quinolone


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.

quin·o·lone

 (kwĭn′ə-lōn′)
n.
Any of a class of synthetic broad-spectrum antibacterial drugs derived from quinoline compounds.

quinolone

(ˈkwɪnəˌləʊn)
n
1. (Pharmacology) any of a group of synthetic antibiotics, including ciprofloxacin, that inactivate an enzyme required for the replication of certain microorganisms
2. (Pathology) any of a group of synthetic antibiotics, including ciprofloxacin, that inactivate an enzyme required for the replication of certain microorganisms
References in periodicals archive ?
Media Contact: Rachel Brummert, Quinolone Vigilance Foundation, 609-575-9839, rachel@saferpills.
The reports indicated a rapid onset of peripheral neuropathy, often within a few days of starting the quinolone.
Roman Manetsch, PhD, USF associate professor of chemistry, and Dennis Kyle, PhD, USF professor of global health, were co-leaders of the USF team, which helped to discover and develop a series of potent compounds to combat malaria known as the 4-(1H)-quinolone-3-diarylethers, or quinolones.
Between 1998 and 2009, outpatient prescribing of first-line antibiotics for uncomplicated cystitis in women remained constant--yet the number of quinolone prescriptions grew significantly, results from an analysis of national data demonstrated.
Nalidixic acid, the first quinolone introduced into clinical practice, was developed in the 1960s; its use was largely confined to the treatment of urinary tract infections.
OBJECTIVES: We investigated the distribution of plasmid-mediated quinolone resistance (PMQR) genes from swine feedlots and their surrounding environment.
New otic quinolone formulations are being investigated as a possible treatment for AOMT, otitis externa, otitis media with a perforated tympanic membrane, and chronic suppurative otitis media.
3%, its proprietary ophthalmic solution based on a new quinolone antibiotic on May 11.
TSE:4503) today announced that they have concluded a basic licensing agreement for the marketing and joint development in Japan of oral formulations of the new-type quinolone antibiotic T-3811 (generic name: garenoxacin) discovered by Toyama.
Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for garenoxacin, a new type of broad-spectrum quinolone antibiotic for treating Gram-positive and Gram-negative bacterial infections, including those caused by anaerobic organisms and resistant bacterial strains.
Encouragingly though, the results presented in Table 1 indicate that mutations in the quinolone resistance determining region (QRDR) of gyrA, grlA and grlB genes of S.